When LC and recovered participants were stratified by the severity of their acute disease, 31.2% of recovered individuals who had experienced severe COVID-19 were a-CL IgM–positive, compared with 9.8% of those with LC (Table 2). This evidence concerns the gene CD40LG and laryngotracheoesophageal cleft.